Insight Molecular Diagnostics Inc. (IMDX)
Develops blood tests that detect cancer progression and organ rejection early using DNA analysis.
$4.61-0.02%Healthcare
StockGlow Score
Leaning Bearish
BearishBullish
1 year ago+80.1%
The outlook
IMDX is trading near multi-month lows, well below both its 50- and 200-day moving averages. Analyst coverage leans bullish with an average price target about 81% above the current level, though the stock's low StockGlow score reflects mixed market sentiment. The current price sits in the lower third of its 52-week range.
What’s behind the score
Price trendBelow its 50- & 200-day averages
52-week range37% of the way from its 52-week low to high
Price targetAvg target +81% vs current price
Analyst price target
~12-month · 3 analysts$8.33average target+80.8% vs now
Now $4.61
Low $4.00High $12.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$148.9M
52-wk high
$8.51
52-wk low
$2.33
50-day avg
$5.53
200-day avg
$5.47
Trailing P/E
—